Co-Director, Marie Josee & Henry Kravis Center for Molecular Oncology, MSKCC
BIOGRAPHY
Speaker
Abstract
Dr. Berger’s session will explore the development of MSK-IMPACT and MSK-ACCESS, MSK’s comprehensive genomic profiling and cfDNA analysis programs. These initiatives address the need for large-scale molecular profiling across diverse tumor types. A key focus will be the role of matched tumor-normal sequencing in reducing biological false positives, ensuring true somatic variants are accurately identified while enabling seamless integration of germline analysis. Dr. Berger will also discuss how SOPHiA GENETICS has become a key collaborator, empowering MSK to expand the accessibility of precision oncology globally through scalable, cloud-based solutions.
Learning Objectives
- Understand the evolution and unique features of MSK’s genomic profiling programs (MSK-IMPACT and MSK-ACCESS) and their role in advancing precision oncology.
- Explore the critical benefits of matched tumor-normal sequencing in reducing biological false positives, enabling accurate somatic variant identification, and enhancing germline analysis.
- Analyze real clinical cases demonstrating how MSK’s genomic technologies inform decision-making.
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
FEB 25, 2025 | 1:00 PM
Quality efforts in the clinical laboratory are always under the microscope- a hyper-focus for laboratorians from start to finish. Recognizing the external factors that affect hemostasis test...
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
Loading Comments...